A New Direction for Alzheimer’s R&D: FDA Outlines Early Disease Pathway
This article was originally published in RPM Report
Executive Summary
Alzheimer’s R&D has suffered multiple failures over the last decade, with no drug found to slow or halt the underlying progression of the disease. Industry’s focus is now on patients at the very earliest stages of Alzheimer’s in the hopes of finding an effective drug before too much damage is done. FDA is meeting sponsors halfway, with a draft guidance outlining approval requirements.
You may also be interested in...
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
FDA Should Let Alzheimer’s Trials Rely On Single Endpoint, Group Says
Informally, FDA appears open to trials that use cognition as the only primary endpoint rather than insisting that products also show benefit on the functional side.
Alzheimer’s Placebo May Become Disease-Modifying Drug For Affiris
Biotech shifts development plans after Phase II study shows surprising, but promising, results – albeit in the wrong arm of the study.